Contact Us
Drug Search Results
Using advanced filters...
Advanced Search [+]

Lurasidone

Alternative Names: lurasidone, latuda, sm-13496
Latest Update: 2025-05-15
Latest Update Note: Clinical Trial Update

Product Description

Lurasidone is a medication used in the treatment of schizophrenia and bipolar depression. It is in the benzisothiazole class of medications. (Sourced from: https://www.ncbi.nlm.nih.gov/books/NBK541057/)

Mechanisms of Action: D2 Antagonist,5-HT2A Antagonist,5-HT7 Antagonist,ADRA2A Antagonist,ADRA2C Antagonist,5-HT1A Agonist

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Approved

Approved Countries: Argentina | Australia | Austria | Bangladesh | Belgium | Brazil | Canada | China | Colombia | Croatia | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | European Medicines Agency | Finland | Germany | Greece | Hong Kong | Hungary | Iceland | India | Ireland | Italy | Japan | Jordan | Latvia | Lebanon | Lithuania | Malaysia | Netherlands | Norway | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Singapore | Slovakia | Slovenia | Spain | Sweden | Switzerland | Taiwan | Turkey | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela

Approved Indications: None

Known Adverse Events: None

Company: Dainippon Sumitomo Pharma America
Company Location:
Company CEO:
Additional Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Lurasidone

Countries in Clinic: Japan

Active Clinical Trial Count: 1

Highest Development Phases

Phase 3: Schizophrenia

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
jRCT2011210024

P3

Recruiting

Schizophrenia

2025-01-31

Recent News Events

Date

Type

Title

05/06/2025

News Article

 Sunshine Biopharma Launches Generic Lurasidone for Schizophrenia in the Canadian Sector of the Global $1.2 Billion Market

04/22/2025

News Article

 Bristol Myers Squibb Announces Topline Results from Phase 3 ARISE Trial Evaluating Cobenfy (xanomeline and trospium chloride) as an Adjunctive Treatment to Atypical Antipsychotics in Adults with Schizophrenia

09/24/2024

News Article

 CRC Expands Medical Leadership Team with Appointment of Accomplished Medical Directors

06/18/2024

News Article

 Seaport Therapeutics Appoints Seasoned Executives to Management Team

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you've used PRYZM, we hope you're able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions